From which clinical trials was the efficacy and safety data for the single‑tablet 1000 mg abiraterone acetate derived?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 8, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Source of Single-Tablet Abiraterone Data

The efficacy and safety data for the single-tablet 1000 mg abiraterone acetate formulation came from three pivotal randomized, placebo-controlled, international phase III clinical trials: COU-AA-301 (post-docetaxel setting), COU-AA-302 (pre-docetaxel setting), and a phase II therapeutic equivalence study for the fine-particle formulation. 1

Original 1000 mg Formulation Clinical Trials

The FDA approval of the standard 1000 mg abiraterone acetate tablet was based on two landmark studies:

COU-AA-301 (Post-Docetaxel Setting)

  • Study design: 1,195 patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel were randomized 2:1 to receive abiraterone acetate 1000 mg orally once daily plus prednisone 5 mg twice daily (n=797) versus placebo plus prednisone (n=398) 1
  • Primary outcome: Overall survival improved from 10.9 months (placebo) to 14.8 months (abiraterone) at interim analysis (HR 0.65, P<0.001), and from 11.2 to 15.8 months at final analysis (HR 0.74, P<0.0001) 2, 1
  • Secondary outcomes: Significant improvements in radiographic progression-free survival, PSA decline, and pain palliation 3

COU-AA-302 (Pre-Docetaxel Setting)

  • Study design: Randomized phase III trial in asymptomatic or minimally symptomatic mCRPC patients without prior chemotherapy 2
  • Primary outcome: Radiographic PFS improved from 8.3 to 16.5 months (HR 0.53, P<0.001) 2
  • Overall survival: At final analysis with 49.2 months median follow-up, OS improved from 30.3 to 34.7 months (HR 0.81, P=0.003) 2

Fine-Particle 500 mg Formulation

In May 2018, the FDA approved a novel fine-particle formulation of abiraterone at 500 mg daily (half the dose of the original formulation) based on bioequivalence studies. 2

Phase II Therapeutic Equivalence Study

  • Study design: 53 patients with mCRPC randomized to 500 mg daily fine-particle formulation plus 4 mg methylprednisolone twice daily versus 1000 mg originator formulation plus 5 mg prednisone twice daily 4, 2
  • Bioequivalence confirmation: Based on serum testosterone levels, PSA response, and abiraterone pharmacokinetics 4, 2
  • Safety profile: Similar rates of total and grade 3/4 adverse events between arms, with musculoskeletal disorders occurring more frequently in the originator-treated patients (37.9% vs 12.5%) 2

Castration-Sensitive Prostate Cancer Expansion

The February 2018 FDA approval for metastatic castration-sensitive prostate cancer (mCSPC) was based on two additional trials:

LATITUDE Trial

  • Study design: 1,199 patients with high-risk mCSPC randomized to abiraterone plus prednisone 5 mg once daily versus placebo 2, 4
  • Primary outcome: OS improved with HR 0.62 (P<0.0001); 3-year OS rates improved from 49% to 66% 2
  • Final analysis: Median OS 53.3 vs 36.5 months (HR 0.66, P<0.0001) after 51.8 months follow-up 4

STAMPEDE Trial

  • Study design: 1,917 patients with heterogeneous castration-sensitive disease (M1, N1, or high-risk M0) 4, 2
  • Primary outcome: OS improved in overall population (HR 0.63, P<0.0001) and across all subgroups 4, 2
  • Key finding: Survival benefit larger in patients <70 years (HR 0.51) versus ≥70 years (HR 0.94), with increased toxicity in older patients 2, 4

Important Clinical Context

All pivotal trials excluded patients with prior ketoconazole treatment for prostate cancer and those with adrenal gland or pituitary disorders. Concurrent spironolactone use was not permitted during study periods. 1 The standard 1000 mg dose must be taken on an empty stomach (fasting), while the fine-particle formulation can be taken with food, representing a significant practical advantage. 4, 2

References

Guideline

prostate cancer, version 4.2023, nccn clinical practice guidelines in oncology.

Journal of the National Comprehensive Cancer Network : JNCCN, 2023

Guideline

prostate cancer, version 3.2012: featured updates to the nccn guidelines.

Journal of the National Comprehensive Cancer Network : JNCCN, 2012

Guideline

prostate cancer, version 3.2026, nccn clinical practice guidelines in oncology.

Journal of the National Comprehensive Cancer Network : JNCCN, 2025

Related Questions

What is the recommended management for abiraterone‑induced dermatologic lesions?
What should I do if I missed two doses of ZyTiga (abiraterone)?
Should Abiraterone acetate (abiraterone) be taken with food or on an empty stomach for optimal absorption in a patient with prostate cancer?
What is the optimal way to take abiraterone acetate, including dose, timing relative to meals, and required prednisone glucocorticoid replacement?
Does abiraterone cause renal impairment?
What is the significance and recommended management of ST‑segment depression in ECG leads V1 to V3?
In a stable 15‑year‑old boy with massive left primary spontaneous pneumothorax and persistent mediastinal shift after three therapeutic needle aspirations (approximately 5 L of air removed), what is the most likely cause of the lung's failure to re‑expand, and should an intercostal chest tube be inserted now rather than continued observation with a non‑rebreather mask?
What dose of hyaluronidase is appropriate to dissolve a hyaluronic‑acid filler migration?
For a 68-year-old male with recent hospitalization for early coronary plaque on chest CT, a history of cholecystectomy with occasional biliary‑duct stone passage, chronic right‑foot edema, hypertension, and pending diabetes work‑up—currently off hydrochlorothiazide, semaglutide (Mounjaro), and fenofibrate, with lisinopril dose being increased, about to start metformin and empagliflozin (Jardiance), continuing aspirin and atorvastatin, having discontinued a short course of celecoxib, using oxycodone sparingly with occasional ibuprofen and acetaminophen, and adhering to a strict low‑fat diet—can you interpret his recent laboratory results?
What medication can be given to an 8-year-old child who is allergic to acetaminophen and ibuprofen?
What is the Eldon (Eledon) clinical trial investigating, who is eligible (adults with type 1 diabetes eligible for pancreatic islet transplantation), what investigational immunosuppressive regimen (anti‑CD40L antibody tegoprubart) is used, and what have been the outcomes to date?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.